Simultaneous quantification of PGI2 and TXA2 metabolites in plasma and urine in NO-deficient mice by a novel UHPLC/MS/MS method.

The balance between vascular prostacyclin (PGI2) generated mainly via cyclooxygenase-2 (COX-2) and its physiological antagonist platelet-derived thromboxane A2 (TXA2) formed by cyclooxygenase-1 (COX-1) determines cardiovascular homeostasis. In the present work, a novel bioanalytical method for simultaneous quantification of stable plasma and urinary metabolites of PGI2 (6-keto-PGF1α, 2,3-dinor-6-keto-PGF1α) and TXA2 (TXB2, 2,3-dinor-TXB2) using ultra high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC/MS/MS) was developed. The method was validated using artificial plasma and urine and linearity range, intra- and inter-day precision and accuracy, recovery of analytes, relative and absolute matrix effect and stability of analytes were determined. The use of artificial biofluids improved the method sensitivity as it eliminated the contribution of endogenous metabolites present in mice plasma and urine to validation procedure. The newly developed and validated method allowed to quantify 6-keto-PGF1α and TXB2 in mice plasma as well as 2,3-dinor-6-keto-PGF1α and 2,3-dinor-TXB2 in urine samples with high sensitivity and accuracy. The calibration range was established from 0.1 to 100ng/mL for all analytes using artificial biofluids and the recoveries were greater than 89.9%. All validated parameters met the criteria of acceptance specified in FDA and EMA guidance. This method was successfully employed for profiling of the changes in PGI2 and TXA2 generation in NO-deficient mice. This work demonstrated that NO-deficiency induced by L-NAME, evidenced by a fall in nitrite in plasma and urine, was associated with platelet activation, robust increase in TXB2 and mild increase in 6-keto-PGF1α concentration in plasma. Changes in 2,3-dinor-6-keto-PGF1α and 2,3-dinor-TXB2 concentration in urine were less evident suggesting that the measurements in plasma better reflect modest changes in PGI2/TXA2 homeostasis than measurements in urine.

[1]  B. Matuszewski.  Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[2]  T. Hishinuma,et al.  Monitoring of the thromboxane A2/prostacyclin ratio in the urine of patients with retinal vascular occlusion through the low-dose-aspirin therapy using the gas chromatography/selected ion monitoring method. , 1999, Prostaglandins & other lipid mediators.

[3]  D. Fitzgerald,et al.  Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. , 2000, Circulation.

[4]  B. Matuszewski,et al.  Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. , 2003, Analytical chemistry.

[5]  G. FitzGerald,et al.  Cyclo-oxygenase products and atherothrombosis. , 2000, Annals of medicine.

[6]  B. Sitek,et al.  Antiatherosclerotic Effects of 1-Methylnicotinamide in Apolipoprotein E/Low-Density Lipoprotein Receptor–Deficient Mice: A Comparison with Nicotinic Acid , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[7]  I. Bernátová.  Endothelial Dysfunction in Experimental Models of Arterial Hypertension: Cause or Consequence? , 2014, BioMed research international.

[8]  H. Seyberth,et al.  Effects of selective COX‐2 inhibition on prostanoids and platelet physiology in young healthy volunteers , 2007, Journal of thrombosis and haemostasis : JTH.

[9]  T. Hishinuma,et al.  Urinary thromboxane A2/prostacyclin balance reflects the pathological state of a diabetic. , 1999, Prostaglandins & other lipid mediators.

[10]  P. Vanhoutte,et al.  Inhibiting the NO pathway with intracoronary L-NAME infusion increases endothelial dysfunction and intimal hyperplasia after heart transplantation. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  Antonín Lojek,et al.  Arginine-Based Inhibitors of Nitric Oxide Synthase: Therapeutic Potential and Challenges , 2012, Mediators of inflammation.

[12]  A. Santoni,et al.  Interplay between Human Cytomegalovirus and Intrinsic/Innate Host Responses: A Complex Bidirectional Relationship , 2012, Mediators of inflammation.

[13]  Garret A. FitzGerald,et al.  Prostaglandins and Inflammation , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[14]  R. Gryglewski,et al.  Endothelial Secretory Function and Atherothrombosis , 2004 .

[15]  Z. Benyó,et al.  Prostacyclin-mediated compensatory mechanism in the coronary circulation during acute NO synthase blockade. , 2003, Life sciences.

[16]  V. Ullrich,et al.  New physiological and pathophysiological aspects on the thromboxane A(2)-prostacyclin regulatory system. , 2001, Biochimica et biophysica acta.